Percentages of patients and controls with antibody reactivity to the peptides tested
| Patient group | Controls | GB1 (early) | GB2 (peak) | GB3 (3 months) | CIDP | ON |
|---|---|---|---|---|---|---|
| CIDP, chronic inflammatory demyelinating polyradiculoneuropathy; GB, Guillain–Barré; ON, other neuropathies. | ||||||
| Samples were considered to have a positive antibody reaction to the peptide tested if the mean OD485nm reading in ELISA for wells containing 5 μg of total IgG was >0.2. The percentage of patients with antibody titre >200 is shown. Patient groups were compared individually with the controls by Fisher’s exact test. | ||||||
| *Two-tailed probability values. | ||||||
| †These results were non-significant. | ||||||
| n | 38 | 28 | 30 | 24 | 36 | 48 |
| Male:female | 19:19 | 31:17 | 24:12 | 24:22 | ||
| Mean age (years) | 42 | 50 | 56 | 57 | ||
| Age range (years) | 21–91 | 18–82 | 25–85 | 27–80 | ||
| Median age (years) | 40 | 52 | 59 | 58 | ||
| Mean (SE) IgG concentration (μg/ml) | 10 022 (435) | 11 502 (1350) | 18 274 (1979) | 11 208 (879) | 10 324 (628) | 9569 (626) |
| Peptide P2 (14–25) | ||||||
| Positive (%) | 5.3 | 21.4 | 43.3 | 25.0 | 8.3 | 16.7 |
| p Value | 0.138 | 0.001* | 0.366 | 0.67 | 0.174 | |
| % titre >200† | 0 | 7.1 | 16.6 | 8.3 | 0 | 0 |
| Peptide P2 (61–70) | ||||||
| Positive (%) | 13.2 | 17.9 | 26.7 | 25.0 | 11.1 | 17.9 |
| p Value | 0.732 | 0.217 | 0.311 | 1 | 0.765 | |
| % titre >200† | 5.3 | 7.1 | 13.3 | 20.8 | 5.5 | 4.1 |
| Peptide P0 (56–71) | ||||||
| Positive (%) | 21.1 | 25.0 | 16.7 | 25.0 | 11.1 | 8.5 |
| p Value | 0.561 | 1 | 0.75 | 0.515 | 0.201 | |
| % titre>200† | 2.6 | 7.1 | 10 | 4.1 | 0 | 2 |
| Peptide P0 (70–85) | ||||||
| Positive (%) | 18.4 | 21.4 | 26.7 | 16.7 | 16.7 | 6.4 |
| p Value | 0.765 | 0.557 | 1 | 1 | 0.103 | |
| % titre >200† | 10 | 7.1 | 6.6 | 4.1 | 5.5 | 2 |
| Peptide P0 (180–199) | ||||||
| Positive (%) | 2.6 | 7.1 | 6.7 | 4.2 | 0 | 8.5 |
| p Value | 0.57 | 0.579 | 1 | 1 | 0.375 | |
| % titre >200† | 0 | 7.1 | 2.6 | 4.1 | 0 | 2 |